Real-world clinical outcomes among patients with metastatic castration-sensitive prostate cancer initiating apalutamide
Future Oncology, 2024
Aim
To describe overall survival, time to castration resistance and castration resistance-free survival in patients with metastatic castration-sensitive prostate cancer (mCSPC) initiating apalutamide in a US oncology network.
Patients & methods
Patients with mCSPC initiating apalutamide on or after 17 September 2019 from an electronic health record-derived deidentified database were included. Patients were followed from apalutamide initiation and were censored at the earlier of end of clinical activity or data availability (31 October 2022).
Results
At 12 and 24 months, overall survival rates were 91.0 and 88.3%, rates of castration sensitivity were 85.7 and 72.1%, and castration resistance-free survival rates were 80.2 and 65.9%, respectively.
Conclusion
Real-world clinical outcomes of patients with mCSPC treated with apalutamide were comparable to results from the phase III TITAN trial.
Authors
Lowentritt BH, Du S, Rossi C, Muser E, Khilfeh I, Kinkead F, Korsiak J, Lefebvre P, Pilon D, Agarwal N